is the exclusive partner of Caris Molecular Intelligence
in Australia and New Zealand.
We are responsible for sending tumour specimens to the Caris laboratory in the United States for testing and providing the results to the treating physician.
At the lab, Caris Molecular Intelligence® (CMI) examines the molecular makeup that is unique to each patient’s tumour.
It uses multiple molecular testing technologies – including Immunohistochemistry, in situ Hybridization, 46- and 592-gene Next-Generation Sequencing (NGS), Sanger Sequencing, Pyro Sequencing and Fragment Analysis to detect and analyse biomarkers.
CMI then compares the tumour’s information with an exhaustive review of literature from thousands of the world’s leading cancer researchers, correlating biomarker to drug responses.
The results provide oncologists with information about which treatments are likely to be most effective and which treatments are likely to be ineffective for each individual patient so that an oncologist can personalise cancer treatment based on the biology of their patient’s tumour.
The test may only be ordered by your oncologist. If you would like to investigate the possibility of ordering molecular testing, please discuss this with your oncologist.
This brochure discusses how Caris Molecular Intelligence is used to provide actionable treatment options. You may print this brochure and take it to your next appointment to discuss with your oncologist.